Mele, G., Cascavilla, N., Di Renzo, N., Guarini, A., Mazza, P., Melillo, L., . . . Pastore, D. (2022). Daratumumab plus bortezomib or daratumumab plus lenalidomide as salvage therapy for patients with myeloma. Annals of Hematology, 101(8), 1727. https://doi.org/10.1007/s00277-022-04857-0
Chicago-referens (17:e uppl.)Mele, G., et al. "Daratumumab Plus Bortezomib or Daratumumab Plus Lenalidomide as Salvage Therapy for Patients with Myeloma." Annals of Hematology 101, no. 8 (2022): 1727. https://doi.org/10.1007/s00277-022-04857-0.
MLA-referens (9:e uppl.)Mele, G., et al. "Daratumumab Plus Bortezomib or Daratumumab Plus Lenalidomide as Salvage Therapy for Patients with Myeloma." Annals of Hematology, vol. 101, no. 8, 2022, p. 1727, https://doi.org/10.1007/s00277-022-04857-0.
